Vestal Point Capital, LP Astria Therapeutics, Inc. Transaction History
Vestal Point Capital, LP
- $1.4 Trillion
- Q1 2025
A detailed history of Vestal Point Capital, LP transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Vestal Point Capital, LP holds 4,180,000 shares of ATXS stock, worth $17.1 Million. This represents 1.59% of its overall portfolio holdings.
Number of Shares
4,180,000
Previous 4,180,000
-0.0%
Holding current value
$17.1 Million
Previous $37.4 Billion
40.27%
% of portfolio
1.59%
Previous 2.22%
Shares
4 transactions
Others Institutions Holding ATXS
# of Institutions
119Shares Held
51.1MCall Options Held
5.3KPut Options Held
6.1K-
Perceptive Advisors LLC New York, NY6.49MShares$26.5 Million1.45% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.11MShares$20.9 Million0.57% of portfolio
-
Fcpm Iii Services B.V. Naarden, P73.82MShares$15.6 Million4.93% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.55MShares$14.5 Million6.47% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$14.4 Million0.0% of portfolio
About Astria Therapeutics, Inc.
- Ticker ATXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,178,000
- Market Cap $62.1M
- Description
- Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...